Patients who have had a stroke are prescribed medication to prevent new strokes. Nevertheless, fewer than half achieve the ...

Topline data show the Factor XIa inhibitor asundexian lowers recurrent stroke risk vs placebo with no increase in major bleeding events.

Bayer AG BAYRY announced that pipeline candidate asundexian met primary efficacy and safety endpoints in late-stage OCEANIC-STROKE Study in secondary stroke prevention. Results from the study showed ...

Ultimately, investigators found a significant reduction in ischemic stroke risk with asundexian compared to placebo, both in combination with antiplatelet therapy. Additionally, participants had no ...

Findings are respite for German conglomerate facing sliding sales of blockbuster drugs and US legal challenges ...

A transient ischemic attack (TIA), often referred to as a mini-stroke, happens when a temporary interruption of blood flow to the brain is caused by a blood clot or narrowed blood vessels. TIAs last ...

Coronary heart disease, stroke, and chronic obstructive pulmonary disease are the top three causes of death worldwide, accounting for an estimated 1 and 3 deaths, per the World Health Organization ...

Please provide your email address to receive an email when new articles are posted on . Liraglutide may improve outcomes and prognosis after minor stroke/transient ischemic attack in patients with ...

A new study suggests that in healthy older adults, the risks of taking a daily low-dose aspirin outweigh any potential benefits in stroke reduction. Published on July 26 in JAMA Network Open, ...

Fatigue, a common symptom immediately after a transient ischemic attack (TIA), persists up to a year after the event in 53.8% of patients, a new study showed. History of anxiety or depression was ...